Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Recursion Pharmaceuticals ( (RXRX) ) has provided an update.
Recursion Pharmaceuticals announced significant leadership changes effective January 1, 2026, with Najat Khan, Ph.D., appointed as the new Chief Executive Officer and President, while Christopher Gibson, Ph.D., transitions to Chair of the Board. This leadership transition is accompanied by a strong financial performance, with the company achieving over $500 million in milestone and upfront payments from partnerships, including a recent $30 million milestone from Roche and Genentech. The company continues to advance its internal and partnered programs, leveraging its AI-driven platform, Recursion OS, to drive innovation in drug discovery and development.
The most recent analyst rating on (RXRX) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
Recursion Pharmaceuticals’ overall stock score is primarily impacted by its financial performance challenges, including negative profit margins and cash flow issues. The earnings call provided positive insights into technological advancements and cash management, but concerns about long development timelines and reliance on partnerships remain. Technical analysis and valuation indicate moderate risk, with potential volatility.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals is a leading clinical stage TechBio company focused on decoding biology to radically improve lives. The company specializes in developing an AI-enabled platform that combines massive proprietary datasets with supercomputing capabilities and sophisticated AI models to advance drug discovery and development, particularly in neuroscience and oncology.
Average Trading Volume: 39,089,888
Technical Sentiment Signal: Sell
Current Market Cap: $2.17B
Find detailed analytics on RXRX stock on TipRanks’ Stock Analysis page.